Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OKUR | SC 13G | neutral | 4/10 | Coastlands Capital LP filed a new Schedule 13G disclosing a 6.67% passive stake in OnKure Therapeutics, holding 2,700,00 | Oct 7, 2026 |
| SRZN | SC 13G/A | neutral | 4/10 | Boxer Capital Management, LLC filed an amended Schedule 13G disclosing a 11.6% passive stake in Surrozen, Inc. as of Sep | Oct 7, 2026 |
| SGMT | SC 13G | neutral | 4/10 | Commodore Capital LP filed a Schedule 13G disclosing a 7.6% passive beneficial ownership stake in Sagimet Biosciences as | Oct 7, 2026 |
| NBIX | 3 | neutral | 2/10 | Eiry Roberts, M.D., the new Chief Medical Officer of Neurocrine Biosciences, filed a Form 3 initial statement of benefic | Oct 7, 2026 |
| INM | SC 13G/A | bullish | 5/10 | ADAR1 Capital Management, LLC filed an amended Schedule 13G disclosing a 17.2% passive stake in InMed Pharmaceuticals In | Oct 7, 2026 |
| CTTH | 8-K | bearish | 6/10 | CTT Pharmaceutical Holdings' independent auditor, Holt & Patterson, LLC, resigned effective October 2, 2026, citing a de | Oct 7, 2026 |
| SCNX | 8-K | neutral | 4/10 | Scienture Holdings filed an 8-K confirming a 1-for-25 reverse stock split effective October 5, 2026, aimed at regaining | Oct 7, 2026 |
| QNRX | SC 13G/A | bearish | 5/10 | Ikarian Capital, LLC filed an amended Schedule 13G disclosing a 4.4% passive stake in Quoin Pharmaceuticals Ltd. as of S | Oct 7, 2026 |
| CNEY | 3 | neutral | 2/10 | Chen Jian filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting no securities owned as of | Oct 7, 2026 |
| DCOY | S-1 | bearish | 6/10 | Decoy Therapeutics filed an S-1 registration statement to register up to 2,368,868 shares of common stock for resale by | Oct 7, 2026 |
| PTCT | 144 | neutral | 3/10 | Michael Schmertzler, a director of PTC Therapeutics and affiliate of Section Six Partners, L.P., filed a Form 144 on Oct | Oct 7, 2026 |
| RLAY | 144 | neutral | 2/10 | Sanjiv Patel, a director and officer of Relay Therapeutics, filed a Form 144 notice of intent to sell 96,401 shares of c | Oct 7, 2026 |
| ABUS | SC 13G/A | neutral | 3/10 | Morgan Stanley filed an amended Schedule 13G disclosing a 12.2% passive stake in Arbutus Biopharma Corp as of September | Oct 7, 2026 |
| RGC | 20-F | bearish | 6/10 | Regencell Bioscience Holdings Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2026, reportin | Oct 7, 2026 |
| CDT | SC 13G | neutral | 4/10 | Primary Development Fund (Cayman) SPC and related entities filed a new Schedule 13G disclosing a 9.2% passive stake in C | Oct 7, 2026 |
| RTSN | S-1/A | neutral | 4/10 | Retension Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement solely to update the filing fee table | Oct 7, 2026 |
| MDCX | 8-K | neutral | 4/10 | Medicus Pharma Ltd. announced a 50-to-1 reverse share split effective October 12, 2026, to boost the bid price and regai | Oct 7, 2026 |
| CDT | SC 13G/A | bearish | 5/10 | Mark Taylor and his affiliated entities (Prospect Capital Securities Ltd and Prospect Finance Ltd) filed an amended Sche | Oct 7, 2026 |
| GNTA | 6-K | neutral | 4/10 | The Court of Milan denied minority shareholders' request to suspend the capital increase related to the ATC acquisition, | Oct 7, 2026 |
| CDT | SC 13G/A | bearish | 5/10 | Craig Wigglesworth filed an amended Schedule 13G disclosing a reduced stake in CDT Equity Inc. to 50,322 shares (3.4% of | Oct 7, 2026 |
| PULM | DEFA14A | neutral | 2/10 | Pulmatrix filed a DEFA14A supplement postponing its Special Meeting in lieu of Annual Meeting from October 16, 2026 to O | Oct 7, 2026 |
| EBS | 144 | neutral | 2/10 | Director Donald DeGolyer filed a Form 144 notice of intent to sell 17,800 common shares of Emergent BioSolutions Inc., w | Oct 7, 2026 |
| GRDX | 8-K | neutral | 3/10 | GridAI Technologies Corp. made a third loan of $536,000 to Pronghorn Resources, LLC, bringing the total aggregate princi | Oct 7, 2026 |
| AQST | SC 13G | neutral | 3/10 | Edward P. Bass and his affiliated entity Thru Line L.P. filed a new Schedule 13G disclosing beneficial ownership of appr | Oct 7, 2026 |
| LLY | 144 | neutral | 3/10 | Lilly Endowment Inc., a major affiliate shareholder of Eli Lilly, filed Form 144 on October 7, 2026, indicating intent t | Oct 7, 2026 |
| BKHA | SC 13G/A | neutral | 3/10 | Wolverine Asset Management LLC filed an amended Schedule 13G disclosing a 5.09% passive stake in Black Hawk Acquisition | Oct 7, 2026 |
| PHGE | 8-K | neutral | 4/10 | Tessera Defense & Homeland Security formalized employment agreements with CEO Michael Oster and CFO David Rokach on Octo | Oct 7, 2026 |
| BCAX | SC 13G/A | neutral | 3/10 | T. Rowe Price Investment Management, Inc. filed an amendment to its Schedule 13G, disclosing a 4.2% passive stake in Bic | Oct 7, 2026 |
| AQST | SC 13G/A | bearish | 6/10 | Douglas K. Bratton and affiliated entities filed an amended Schedule 13G reporting a massive reduction in beneficial own | Oct 7, 2026 |
| VYNE | SC 13G | neutral | 4/10 | Bellevue Group AG, a Swiss asset manager, filed a Schedule 13G disclosing a 10.6% passive stake in Yarrow Bioscience (VY | Oct 7, 2026 |